232 related articles for article (PubMed ID: 16099956)
1. HIV/AIDS. Report of novel treatment aimed at latent HIV raises the 'c word'.
Cohen J
Science; 2005 Aug; 309(5737):999-1000. PubMed ID: 16099956
[No Abstract] [Full Text] [Related]
2. Anti-HIV agents. Valproic acid and HIV eradication--many questions remain.
TreatmentUpdate; 2005; 17(6):5-7. PubMed ID: 17228476
[No Abstract] [Full Text] [Related]
3. Valproic acid: a potential role in treating latent HIV infection.
Routy JP
Lancet; 2005 Aug 13-19; 366(9485):523-4. PubMed ID: 16099272
[No Abstract] [Full Text] [Related]
4. The emerging race to cure HIV infections.
Cohen J
Science; 2011 May; 332(6031):784-5, 787-9. PubMed ID: 21566173
[No Abstract] [Full Text] [Related]
5. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.
Routy JP; Tremblay CL; Angel JB; Trottier B; Rouleau D; Baril JG; Harris M; Trottier S; Singer J; Chomont N; Sékaly RP; Boulassel MR
HIV Med; 2012 May; 13(5):291-6. PubMed ID: 22276680
[TBL] [Abstract][Full Text] [Related]
6. Fusion inhibitors: T-20 and T-1249.
TreatmentUpdate; 2001; 12(12):2-3. PubMed ID: 11570088
[No Abstract] [Full Text] [Related]
7. Katy, bar the door! HIV entry inhibitors.
Martinez LJ
Res Initiat Treat Action; 2000 Jun; 6(2):6-12. PubMed ID: 11707878
[No Abstract] [Full Text] [Related]
8. Can HIV infection be eradicated through use of potent antiviral agents?
Josefsson L; Dahl V; Palmer S
Curr Opin Infect Dis; 2010 Dec; 23(6):628-32. PubMed ID: 20847693
[TBL] [Abstract][Full Text] [Related]
9. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir.
Sagot-Lerolle N; Lamine A; Chaix ML; Boufassa F; Aboulker JP; Costagliola D; Goujard C; Pallier C; Delfraissy JF; Lambotte O;
AIDS; 2008 Jun; 22(10):1125-9. PubMed ID: 18525257
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Archin NM; Cheema M; Parker D; Wiegand A; Bosch RJ; Coffin JM; Eron J; Cohen M; Margolis DM
PLoS One; 2010 Feb; 5(2):e9390. PubMed ID: 20186346
[TBL] [Abstract][Full Text] [Related]
11. [HIV may be cured].
Kjær AS; Østergaard HB
Ugeskr Laeger; 2015 Apr; 177(17):. PubMed ID: 25922162
[TBL] [Abstract][Full Text] [Related]
12. The challenge of finding a cure for HIV infection.
Richman DD; Margolis DM; Delaney M; Greene WC; Hazuda D; Pomerantz RJ
Science; 2009 Mar; 323(5919):1304-7. PubMed ID: 19265012
[TBL] [Abstract][Full Text] [Related]
13. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals.
Trono D; Van Lint C; Rouzioux C; Verdin E; Barré-Sinoussi F; Chun TW; Chomont N
Science; 2010 Jul; 329(5988):174-80. PubMed ID: 20616270
[TBL] [Abstract][Full Text] [Related]
14. The development of immune-modulating compounds to disrupt HIV latency.
Remoli AL; Marsili G; Battistini A; Sgarbanti M
Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
[TBL] [Abstract][Full Text] [Related]
15. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
16. [T-20: a fusion inhibitor].
Iafolla M
Sidahora; 2002; (3):20-2. PubMed ID: 12703471
[No Abstract] [Full Text] [Related]
17. Therapies. Raising the limits.
Cohen J
Science; 2002 Jun; 296(5577):2322. PubMed ID: 12089423
[No Abstract] [Full Text] [Related]
18. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy.
Blazkova J; Chun TW; Belay BW; Murray D; Justement JS; Funk EK; Nelson A; Hallahan CW; Moir S; Wender PA; Fauci AS
J Infect Dis; 2012 Sep; 206(5):765-9. PubMed ID: 22732922
[TBL] [Abstract][Full Text] [Related]
19. Progress and challenges in the use of latent HIV-1 reactivating agents.
Shang HT; Ding JW; Yu SY; Wu T; Zhang QL; Liang FJ
Acta Pharmacol Sin; 2015 Aug; 36(8):908-16. PubMed ID: 26027656
[TBL] [Abstract][Full Text] [Related]
20. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.
Chun TW; Justement JS; Moir S; Hallahan CW; Maenza J; Mullins JI; Collier AC; Corey L; Fauci AS
J Infect Dis; 2007 Jun; 195(12):1762-4. PubMed ID: 17492591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
